Mercer Global Advisors
NBIX icon

Mercer Global Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Mercer Global Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.94M Buy
60,275
+19,318
+47% +$2.56M 0.01% 590
2025
Q4 		$5.81M Buy
40,957
+9,355
+30% +$1.36M 0.01% 668
2025
Q3 		$4.44M Buy
31,602
+17,641
+126% +$2.39M 0.01% 716
2025
Q2 		$1.75M Buy
13,961
+1,979
+17% +$227K ﹤0.01% 943
2025
Q1 		$1.33M Sell
11,982
-130
-1% -$16.5K ﹤0.01% 995
2024
Q4 		$1.65M Buy
12,112
+4,143
+52% +$512K ﹤0.01% 890
2024
Q3 		$911K Sell
7,969
-154
-2% -$21.1K ﹤0.01% 1052
2024
Q2 		$1.12M Buy
8,123
+430
+6% +$59K ﹤0.01% 925
2024
Q1 		$1.06M Buy
7,693
+2,401
+45% +$328K ﹤0.01% 937
2023
Q4 		$697K Buy
5,292
+1,219
+30% +$140K ﹤0.01% 1142
2023
Q3 		$458K Buy
4,073
+698
+21% +$73.5K ﹤0.01% 1294
2023
Q2 		$318K Buy
3,375
+121
+4% +$11.8K ﹤0.01% 1485
2023
Q1 		$329K Buy
3,254
+168
+5% +$17.5K ﹤0.01% 1453
2022
Q4 		$369K Buy
3,086
+259
+9% +$30.3K ﹤0.01% 1382
2022
Q3 		$300K Sell
2,827
-540
-16% -$54.8K ﹤0.01% 1409
2022
Q2 		$328K Buy
3,367
+430
+15% +$39.7K ﹤0.01% 1380
2022
Q1 		$275K Buy
+2,937
New +$249K ﹤0.01% 1555
2021
Q2 		– Sell
-2,960
Closed -$288K – 1717
2021
Q1 		$288K Buy
2,960
+568
+24% +$59.6K ﹤0.01% 1329
2020
Q4 		$229K Buy
+2,392
New +$231K ﹤0.01% 1176
2020
Q3 		– Sell
-1,842
Closed -$225K – 1270
2020
Q2 		$225K Buy
+1,842
New +$204K ﹤0.01% 957

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mercer Global Advisors's NBIX Position: Q1 2026 in Review

Mercer Global Advisors increased its Neurocrine Biosciences (NBIX) stake by 47% in Q1 2026, buying an estimated $2.56M and bringing the position to 60,275 shares worth $7.94M. The position accounts for 0.01% of the portfolio, ranked #590.

Mercer Global Advisors first reported a position in NBIX in Q2 2020 and has held it in 20 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Mercer Global Advisors held 60,275 shares of Neurocrine Biosciences worth $7.94M as of Q1 2026.
  • Mercer Global Advisors bought 19,318 Neurocrine Biosciences shares in Q1 2026, an estimated $2.56M.
  • Neurocrine Biosciences made up 0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #590 holding.
  • Mercer Global Advisors first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 20 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.